Gene therapy cures for hereditary genetic conditions are likely to reach the United States market in the coming decades. Several disease areas with potential cures are orphan conditions, which affect … Read More
Patient & Caregiver Themes Survey
Patients and caregivers are key stakeholders in the development of system-wide, implementable precision financing models for durable and curative therapies. Patient and caregiver challenges are generally assumed to be primarily … Read More
Address: From Bigger Data to Smarter Evidence
On Tuesday, February 26th, Dr Gigi Hirsch, Executive Director of MIT NEWDIGS, gave a presentation for the Harvard-MIT Center for Regulatory Science to a gathering of local academic, clinical, and industry leaders … Read More
Preparing Patients and the Health System for Curative Therapies in the Pipeline
American Journal of Managed Care Curative therapies represent a conundrum for healthcare. On the one hand, there is the ability to cure patients of potentially life-threatening diseases or diseases that … Read More
MIT Releases New Policy and Practice Suggestions to Make Cures Accessible and Sustainable
Innovative Therapies Will Require Innovations in Financing and Regulations WASHINGTON, DC, February 12—Today, the MIT-based Financing and Reimbursement of Cures in the US (FoCUS) consortium released a series of large-scale … Read More
“Dynamic Dossier in the Cloud” to Transform Data Sharing, Starting with Federal Regulators
New platform will redefine biopharmaceutical data sharingMIT NEWDIGS and the Harvard-MIT Center for Regulatory Science announced the Dynamic Dossier in the Cloud today, a radical new platform that promises to … Read More
Precision Financing of Durable, Potentially Curative Therapies
Pharmaceutical Executive, January 27, 2019 Trusheim, Jane Barlow Russell Teagarden Mark Gene therapies and cellular treatments create multiple financial challenges for US healthcare payers beyond price. The work of the … Read More
Precision Financing Solutions for Durable / Potentially Curative Therapies
The NEWDIGS FoCUS consortium of multiple stakeholders (payers, providers, patient advocacy organizations, pharmaceutical developers, academics and others) has been working collaboratively since 2016 to address the need for new, innovative … Read More
Incorporation of Value-Based Payment Agreements into the Calculation of Medicaid Drug Rebates
Value-Based Payment (VBP) agreements will play an important role in mitigating uncertainty in durable therapies, where it is unclear whether a large upfront payment is justified based on limited clinical … Read More